Structure Therapeutics Inc · Q1 2025 earnings

Briefing

Structure Therapeutics reported a net loss of $46.833 million for Q1 2025, with increased operating expenses driven by research and development, and a higher interest and other income.

Structure Therapeutics Inc. reported a net loss of $46.833 million for the three months ended March 31, 2025, compared to a net loss of $26.036 million for the same period in 2024. This increased loss was primarily due to a significant rise in research and development expenses, which more than doubled year-over-year, and an increase in general and administrative costs. The company's cash and cash equivalents, along with short-term investments, totaled $836.9 million as of March 31, 2025, which management believes is sufficient to fund operations through at least 2027.

• Net loss increased to $46.833 million in Q1 2025 from $26.036 million in Q1 2024, primarily due to higher operating expenses.
• Research and development expenses significantly increased by 107% to $42.867 million, driven by preclinical research, clinical trial costs, and employee expenses.
• General and administrative expenses rose by 19% to $13.444 million, mainly due to increased employee expenses as the company expanded its infrastructure.
• Interest and other income, net, increased to $9.576 million in Q1 2025 from $6.008 million in Q1 2024, reflecting higher interest income from cash and investments.

Headline financials

Revenue & EPS history

Structure Therapeutics expects to continue incurring significant operating losses as it invests in research and development, expands its product pipeline, and seeks regulatory approvals. The company anticipates needing substantial additional capital to fund Phase 3 clinical studies and future operations, with current capital expected to last through at least 2027.